23 Jul, 2026
According to Straits Research, the global peptide synthesis market size was valued at $750.67 million in 2025 and is projected to grow from $844.5 million in 2026 to $2,166.81 million by 2034, registering a CAGR of 12.5% during the forecast period 2026–2034.
Peptide synthesis involves the formation of peptides by the sequential linkage of amino acids. Peptides are concise sequences of amino acids, crucial for numerous biological processes. Peptide synthesis is essential in drug discovery, diagnostics, and manufacturing vaccines, hormones, and enzymes. It is used in the pharmaceutical, biotechnology, and research sectors to advance peptide-based medicines, vaccines, and other biopharmaceuticals. Owing to their selectivity and reduced adverse effects, peptides are progressively utilized as targeted treatments, rendering peptide synthesis essential in advanced pharmaceutical research.
The demand for peptide-based medicines is a primary catalyst for the peptide synthesis market. The rising incidence of chronic diseases, including cancer, diabetes, and neurological disorders, has heightened the demand for targeted peptide treatments. Furthermore, innovations in peptide synthesis technologies, including solid-phase peptide synthesis (SPPS) and microwave-assisted peptide synthesis, have enhanced the efficiency and yield of peptide manufacturing. The growing emphasis on customized medicine and biologics within the healthcare sector is propelling the usage of peptides, hence stimulating market expansion.
The increase in demand for peptide-based therapies is a significant factor propelling the worldwide peptide synthesis market. Peptides are progressively preferred in pharmacological development owing to their elevated specificity, lower toxicity, and effectiveness in regulating intricate biological processes. Their capacity to target protein-protein interactions and bind to receptors with high affinity renders them optimal for treating diseases such as cancer, metabolic disorders, cardiovascular problems, and autoimmune diseases.
The increasing pipeline of peptide medications in clinical trials and the growing number of regulatory approvals indicate that the market is set for significant growth in the coming decade.
The increasing utilization of peptide synthesis in vaccine development and diagnostic testing offers significant potential prospects for the global industry. In recent years, peptides have become essential in developing next-generation vaccines, particularly as epitope-based vaccinations that elicit focused and safer immune responses. Companies such as CureVac and Boehringer Ingelheim are utilizing synthetic peptides to formulate mRNA vaccines, wherein peptides facilitate the synthesis of antigenic proteins.
With global healthcare systems emphasizing early detection and precision medicine, the need for peptide-based tools is anticipated to increase, generating significant potential for synthesis technology suppliers in both therapeutic and diagnostic fields.
Europe possesses the predominant market share in the worldwide peptide synthesis sector, attributed to its robust pharmaceutical and biotechnology industries. Germany, the United Kingdom, and France have a strong research foundation and host numerous prominent entities in peptide therapies, including Bayer and Roche. The region is renowned for its stringent and superior manufacturing standards, establishing it as a center for peptide-based medicine research. EIT Health, a European initiative, endorses biotech businesses specializing in peptide-based therapies, fostering innovation in peptide therapeutics and drug development. Europe's emphasis on regulatory compliance and environmental practices, particularly in biologics production, significantly contributes to the expansion of the peptide synthesis market.
sales@straitsresearch.com